Alcoholic liver disease care near burlingame

1. Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001–2002 to 2012–2013: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry. 2017;74(9):911–23. [PMC free article] [PubMed] [Google Scholar]

2. Grucza RA, Sher KJ, Kerr WC, Krauss MJ, Lui CK, McDowell YE, et al. Trends in Adult Alcohol Use and Binge Drinking in the Early 21st-Century United States: A Meta-Analysis of 6 National Survey Series. Alcohol Clin Exp Res. 2018;42(10):1939–50. [PMC free article] [PubMed] [Google Scholar]

3. Kim D, Li AA, Gadiparthi C, Khan MA, Cholankeril G, Glenn JS, et al. Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology. 2018;155(4):1154–63 e3. [PMC free article] [PubMed] [Google Scholar]

4. Cholankeril G, Ahmed A. Alcoholic Liver Disease Replaces Hepatitis C Virus Infection as the Leading Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol. 2018;16(8):1356–8. [PMC free article] [PubMed] [Google Scholar]

5. Rubin E, Lieber CS. Early fine structural changes in the human liver induced by alcohol. Gastroenterology. 1967;52(1):1–13. [PubMed] [Google Scholar]

6. Parker R, Aithal GP, Becker U, Gleeson D, Masson S, Wyatt JI, et al. Natural history of histologically proven alcohol-related liver disease: A systematic review. J Hepatol. 2019. [PubMed] [Google Scholar]

7. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S87–96. [PubMed] [Google Scholar]

8. Mellinger JL, Shedden K, Winder GS, Tapper E, Adams M, Fontana RJ, et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology. 2018;68(3):872–82. [PubMed] [Google Scholar]

9. Sofair AN, Barry V, Manos MM, Thomas A, Zaman A, Terrault NA, et al. The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance. J Clin Gastroenterol. 2010;44(4):301–7. [PubMed] [Google Scholar]

10. Askgaard G, Leon DA, Kjaer MS, Deleuran T, Gerds TA, Tolstrup JS. Risk for alcoholic liver cirrhosis after an initial hospital contact with alcohol problems: A nationwide prospective cohort study. Hepatology. 2017;65(3):929–37. [PubMed] [Google Scholar]

11. Westwood G, Meredith P, Atkins S, Greengross P, Schmidt PE, Aspinall RJ. Universal screening for alcohol misuse in acute medical admissions is feasible and identifies patients at high risk of liver disease. J Hepatol. 2017;67(3):559–67. [PubMed] [Google Scholar]

12. Udo T, Vasquez E, Shaw BA. A lifetime history of alcohol use disorder increases risk for chronic medical conditions after stable remission. Drug Alcohol Depend. 2015;157:68–74. [PubMed] [Google Scholar]

13. Kalinowski A, Humphreys K. Governmental standard drink definitions and low-risk alcohol consumption guidelines in 37 countries. Addiction. 2016;111(7):1293–8. [PubMed] [Google Scholar]

14. Rehm J, Patra J. Different guidelines for different countries? On the scientific basis of low-risk drinking guidelines and their implications. Drug Alcohol Rev. 2012;31(2):156–61. [PubMed] [Google Scholar]

15. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet. 2018;391(10129):1513–23. [PMC free article] [PubMed] [Google Scholar]

16. Rehm J, Baliunas D, Borges GL, Graham K, Irving H, Kehoe T, et al. The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction. 2010;105(5):817–43. [PMC free article] [PubMed] [Google Scholar]

17. Cao Y, Willett WC, Rimm EB, Stampfer MJ, Giovannucci EL. Light to moderate intake of alcohol, drinking patterns, and risk of cancer: results from two prospective US cohort studies. BMJ. 2015;351:h4238. [PMC free article] [PubMed] [Google Scholar]

18. Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA. 2011;306(17):1884–90. [PMC free article] [PubMed] [Google Scholar]

19. Savolainen VT, Liesto K, Mannikko A, Penttila A, Karhunen PJ. Alcohol consumption and alcoholic liver disease: evidence of a threshold level of effects of ethanol. Alcohol Clin Exp Res. 1993;17(5):1112–7. [PubMed] [Google Scholar]

20. Savolainen V, Perola M, Lalu K, Penttila A, Virtanen I, Karhunen PJ. Early perivenular fibrogenesis--precirrhotic lesions among moderate alcohol consumers and chronic alcoholics. J Hepatol. 1995;23(5):524–31. [PubMed] [Google Scholar]

21. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut. 1997;41(6):845–50. [PMC free article] [PubMed] [Google Scholar]

22. Sorensen TI, Orholm M, Bentsen KD, Hoybye G, Eghoje K, Christoffersen P. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet. 1984;2(8397):241–4. [PubMed] [Google Scholar]

23. Rehm J, Taylor B, Mohapatra S, Irving H, Baliunas D, Patra J, et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 2010;29(4):437–45. [PubMed] [Google Scholar]

24. Kondili LA, Taliani G, Cerga G, Tosti ME, Babameto A, Resuli B. Correlation of alcohol consumption with liver histological features in non-cirrhotic patients. Eur J Gastroenterol Hepatol. 2005;17(2):155–9. [PubMed] [Google Scholar]

25. Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23(5):1025–9. [PubMed] [Google Scholar]

26. Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol. 2005;3(12):1260–8. [PubMed] [Google Scholar]

27. Hagstrom H, Hemmingsson T, Discacciati A, Andreasson A. Alcohol consumption in late adolescence is associated with an increased risk of severe liver disease later in life. J Hepatol. 2018;68(3):505–10. [PubMed] [Google Scholar]

28. Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol. 1992;136(10):1248–57. [PubMed] [Google Scholar]

29. Dam MK, Flensborg-Madsen T, Eliasen M, Becker U, Tolstrup JS. Smoking and risk of liver cirrhosis: a population-based cohort study. Scand J Gastroenterol. 2013;48(5):585–91. [PubMed] [Google Scholar]

30. White GE, Courcoulas AP, Richardson GA, Mair C, King WC. Alcohol Use Thresholds for Identifying Alcohol-related Problems Before and Following Roux-en-Y Gastric Bypass. Ann Surg. 2018. [PubMed] [Google Scholar]

31. Askgaard G, Gronbaek M, Kjaer MS, Tjonneland A, Tolstrup JS. Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study. J Hepatol. 2015;62(5):1061–7. [PubMed] [Google Scholar]

32. Buch S, Stickel F, Trepo E, Way M, Herrmann A, Nischalke HD, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet. 2015;47(12):1443–8. [PubMed] [Google Scholar]

33. Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, et al. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J Med. 2018;378(12):1096–106. [PMC free article] [PubMed] [Google Scholar]

34. Harris R, Harman DJ, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol Hepatol. 2017;2(4):288–97. [PubMed] [Google Scholar]

35. Agbim U, Asrani SK. Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. Expert Rev Gastroenterol Hepatol. 2019;13(4):361–74. [PubMed] [Google Scholar]

36. Cook PA, Morleo M, Billington D, Sanderson-Shortt K, Jones C, Gabbay M, et al. Evaluation of work-based screening for early signs of alcohol-related liver disease in hazardous and harmful drinkers: the PrevAIL study. BMC Public Health. 2015;15:532. [PMC free article] [PubMed] [Google Scholar]

37. Sheron N, Moore M, O’Brien W, Harris S, Roderick P. Feasibility of detection and intervention for alcohol-related liver disease in the community: the Alcohol and Liver Disease Detection study (ALDDeS). Br J Gen Pract. 2013;63(615):e698–705. [PMC free article] [PubMed] [Google Scholar]

38. Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. Gastroenterology. 2018;154(5):1369–79. [PubMed] [Google Scholar]

39. Pavlov CS, Casazza G, Nikolova D, Tsochatzis E, Gluud C. Systematic review with meta-analysis: diagnostic accuracy of transient elastography for staging of fibrosis in people with alcoholic liver disease. Aliment Pharmacol Ther. 2016;43(5):575–85. [PubMed] [Google Scholar]

40. Nguyen-Khac E, Thiele M, Voican C, Nahon P, Moreno C, Boursier J, et al. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(9):614–25. [PubMed] [Google Scholar]

41. Gianni E, Forte P, Galli V, Razzolini G, Bardazzi G, Annese V. Prospective Evaluation of Liver Stiffness Using Transient Elastography in Alcoholic Patients Following Abstinence. Alcohol Alcohol. 2017;52(1):42–7. [PubMed] [Google Scholar]

42. Thiele M, Detlefsen S, Sevelsted Moller L, Madsen BS, Fuglsang Hansen J, Fialla AD, et al. Transient and 2-Dimensional Shear-Wave Elastography Provide Comparable Assessment of Alcoholic Liver Fibrosis and Cirrhosis. Gastroenterology. 2016;150(1):123–33. [PubMed] [Google Scholar]

43. Shah ND, Ventura-Cots M, Abraldes JG, Alboraie M, Alfadhli A, Argemi J, et al. Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. Clin Gastroenterol Hepatol. 2019;17(11):2320–9 e12. [PMC free article] [PubMed] [Google Scholar]

44. Reinert DF, Allen JP. The Alcohol Use Disorders Identification Test (AUDIT): a review of recent research. Alcohol Clin Exp Res. 2002;26(2):272–9. [PubMed] [Google Scholar]

45. Fiellin DA, Reid MC, O’Connor PG. Screening for alcohol problems in primary care: a systematic review. Arch Intern Med. 2000;160(13):1977–89. [PubMed] [Google Scholar]

46. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158(16):1789–95. [PubMed] [Google Scholar]

47. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res. 2007;31(7):1208–17. [PubMed] [Google Scholar]

48. Schomerus G, Lucht M, Holzinger A, Matschinger H, Carta MG, Angermeyer MC. The stigma of alcohol dependence compared with other mental disorders: a review of population studies. Alcohol Alcohol. 2011;46(2):105–12. [PubMed] [Google Scholar]

49. Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology. 1988;95(4):1056–62. [PubMed] [Google Scholar]

50. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94(4):1018–22. [PubMed] [Google Scholar]

51. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998;93(1):44–8. [PubMed] [Google Scholar]

52. Dunn W, Angulo P, Sanderson S, Jamil LH, Stadheim L, Rosen C, et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology. 2006;131(4):1057–63. [PMC free article] [PubMed] [Google Scholar]

53. Muga R, Sanvisens A, Jarrin I, Fuster D, Bolao F, Tor J, et al. Hepatitis C infection substantially reduces survival of alcohol-dependent patients. Clin Epidemiol. 2018;10:897–905. [PMC free article] [PubMed] [Google Scholar]

54. Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, et al. Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology. 2016;150(4):785–90. [PMC free article] [PubMed] [Google Scholar]

55. Morini L, Politi L, Groppi A, Stramesi C, Polettini A. Determination of ethyl glucuronide in hair samples by liquid chromatography/electrospray tandem mass spectrometry. J Mass Spectrom. 2006;41(1):34–42. [PubMed] [Google Scholar]

56. Appenzeller BM, Agirman R, Neuberg P, Yegles M, Wennig R. Segmental determination of ethyl glucuronide in hair: a pilot study. Forensic Sci Int. 2007;173(2–3):87–92. [PubMed] [Google Scholar]

57. Verbeek J, Crunelle CL, Leurquin-Sterk G, Michielsen PP, De Doncker M, Monbaliu D, et al. Ethyl Glucuronide in Hair Is an Accurate Biomarker of Chronic Excessive Alcohol Use in Patients With Alcoholic Cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):454–6. [PubMed] [Google Scholar]

58. Fagan KJ, Irvine KM, McWhinney BC, Fletcher LM, Horsfall LU, Johnson L, et al. Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers. BMC Gastroenterol. 2014;14:97. [PMC free article] [PubMed] [Google Scholar]

59. Bennett K, Enki DG, Thursz M, Cramp ME, Dhanda AD. Systematic review with meta-analysis: high mortality in patients with non-severe alcoholic hepatitis. Aliment Pharmacol Ther. 2019;50(3):249–57. [PubMed] [Google Scholar]

60. Lackner C, Spindelboeck W, Haybaeck J, Douschan P, Rainer F, Terracciano L, et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol. 2017;66(3):610–8. [PubMed] [Google Scholar]

61. Masson S, Emmerson I, Henderson E, Fletcher EH, Burt AD, Day CP, et al. Clinical but not histological factors predict long-term prognosis in patients with histologically advanced nondecompensated alcoholic liver disease. Liver Int. 2014;34(2):235–42. [PubMed] [Google Scholar]

62. Xie YD, Feng B, Gao Y, Wei L. Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis: A systematic review and meta-analysis. Hepatol Res. 2014;44(4):436–49. [PubMed] [Google Scholar]

63. Gordon MS, Carswell SB, Schadegg M, Mangen K, Merkel K, Tangires S, et al. Avatar-assisted therapy: a proof-of-concept pilot study of a novel technology-based intervention to treat substance use disorders. Am J Drug Alcohol Abuse. 2017;43(5):518–24. [PubMed] [Google Scholar]

64. Khan A, Tansel A, White DL, Kayani WT, Bano S, Lindsay J, et al. Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2016;14(2):191–202 e1–4; quiz e20. [PMC free article] [PubMed] [Google Scholar]

65. Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–17. [PubMed] [Google Scholar]

66. Yoshimura A, Kimura M, Nakayama H, Matsui T, Okudaira F, Akazawa S, et al. Efficacy of disulfiram for the treatment of alcohol dependence assessed with a multicenter randomized controlled trial. Alcohol Clin Exp Res. 2014;38(2):572–8. [PubMed] [Google Scholar]

67. Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014;9(2):e87366. [PMC free article] [PubMed] [Google Scholar]

68. Bjornsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol. 2006;44(4):791–7. [PubMed] [Google Scholar]

69. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915–22. [PubMed] [Google Scholar]

70. Chaignot C, Zureik M, Rey G, Dray-Spira R, Coste J, Weill A. Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France. Pharmacoepidemiol Drug Saf. 2018;27(11):1239–48. [PMC free article] [PubMed] [Google Scholar]

71. Morgan MY, Madden AM, Soulsby CT, Morris RW. Derivation and validation of a new global method for assessing nutritional status in patients with cirrhosis. Hepatology. 2006;44(4):823–35. [PubMed] [Google Scholar]

72. Kim G, Kang SH, Kim MY, Baik SK. Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. PLoS One. 2017;12(10):e0186990. [PMC free article] [PubMed] [Google Scholar]

73. Tandon P, Low G, Mourtzakis M, Zenith L, Myers RP, Abraldes JG, et al. A Model to Identify Sarcopenia in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2016;14(10):1473–80 e3. [PubMed] [Google Scholar]

74. Praktiknjo M, Book M, Luetkens J, Pohlmann A, Meyer C, Thomas D, et al. Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis. Hepatology. 2018;67(3):1014–26. [PubMed] [Google Scholar]

75. Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schutz T, et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr. 2019;38(2):485–521. [PMC free article] [PubMed] [Google Scholar]

76. Cordoba J, Lopez-Hellin J, Planas M, Sabin P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41(1):38–43. [PubMed] [Google Scholar]

77. Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol. 2012;27(3):430–41. [PubMed] [Google Scholar]

78. Trepo E, Ouziel R, Pradat P, Momozawa Y, Quertinmont E, Gervy C, et al. Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease. J Hepatol. 2013;59(2):344–50. [PubMed] [Google Scholar]

79. Shen YC, Chang YH, Fang CJ, Lin YS. Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis. Nutr J. 2019;18(1):34. [PMC free article] [PubMed] [Google Scholar]

80. Castillo-Carniglia A, Keyes KM, Hasin DS, Cerda M. Psychiatric comorbidities in alcohol use disorder. Lancet Psychiatry. 2019. [PMC free article] [PubMed] [Google Scholar]

81. Roerecke M, Rehm J. Cause-specific mortality risk in alcohol use disorder treatment patients: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(3):906–19. [PubMed] [Google Scholar]

82. Vancampfort D, Hallgren M, Mugisha J, De Hert M, Probst M, Monsieur D, et al. The Prevalence of Metabolic Syndrome in Alcohol Use Disorders: A Systematic Review and Meta-analysis. Alcohol Alcohol. 2016;51(5):515–21. [PubMed] [Google Scholar]

83. Kim RG, Loomba R, Prokop LJ, Singh S. Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017;15(10):1521–30 e8. [PMC free article] [PubMed] [Google Scholar]

Page 2

Alcohol Screening Questionnaire (AUDIT): One drink equals: 12oz of beer, 5oz of wine and 1.5oz of hard liquor.